Novartis just bet close to $9 billion on the future of gene therapy, a boost for a field that hasn’t yet seen commercial success. In the same week, GlaxoSmithKline, which has one of the few gene therapies on the market and has struggled to sell it, is asking out. The British pharma giant will send […] https://www.xconomy.com/boston/2018/04/12/as-novartis-buys-into-gene-therapy-gsk-bows-out-with-orchard-deal/
MSD’s Keytruda has significantly increased overall survival in patients with lung cancer patients expressing any level of PD-L1 when used as monotherapy in the first-line setting, potentially significantly increasing the drug’s treatment scope. http://www.pharmatimes.com/news/msds_keytruda_bags_another_trial_success_in_nsclc_1231055
AstraZeneca has licensed a NASH candidate from Ionis. The Big Pharma is paying $30 million upfront to pick up the rights to the program and take it into the clinic. https://www.fiercebiotech.com/biotech/astrazeneca-licenses-ionis-clinical-phase-antisense-nash-drug
(Reuters) – AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off U.S. competition of their biosimilar version to blockbuster drug Humira until 2023.
The European conglomerate will commercialize the South Korean company’s copycat version of Herceptin. https://www.biopharmadive.com/news/mundipharma-inks-third-biosimilar-deal-with-celltrion/519580/
The R&D playbook is evolving as the industry looks to break down the silos between clinical and commercial operations â bringing commercial voices to the earliest phases of asset development. https://www.outsourcing-pharma.com/Article/2018/03/13/Commercial-Trends-Forecast-R-D-is-transforming-into-R-D-C
Novartis is expanding its strategic alliance with Science 37 and has committed to conducting up to 10 new clinical trials â blending both virtual and traditional models â over the next three years. https://www.outsourcing-pharma.com/Article/2018/03/07/Novartis-scaling-site-less-trials-through-expanded-Science-37-alliance
The U.S. Food and Drug Administration (FDA) expanded the dosing schedule for Bristol-Myers Squibb’s Opdivo (nivolumab). https://www.biospace.com/article/fda-expands-bristol-myers-squibb-s-opdivo-dosing-schedule/
Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials https://investor.lilly.com/releasedetail.cfm?ReleaseID=1059806
Clinical Informatics News Contributed Commentary In January 2017, there were 4,003 pharmaceutical companies with nearly 15,000 drugs in the pipeline. Yet only 1 in 5 drugs actually make it to market. Technology inherently aims to streamline processes, eliminate manual effort and create efficiencies, but is technology still doing this for clinical research?